Key Takeaways
- 30% EBITDA milestone hit: EBITDA margin reached 30.0%, which management calls representative of the business nature, driven by operating leverage and a CMS-heavy mix.
- Working capital swelled sharply: Inventories rose ~₹155-160 cr and receivables climbed on uneven order flow, pushing working capital to 155 days and turning pre-cash flow negative by ₹141 crores.
- CMS pipeline churn is normal, not alarming: One Phase-3 intermediate added, one old commercial molecule dropped; the long-awaited molecule is still expected to ship soon.
- Peptide facility is a multi-year bet, not a near-term catalyst: Module-1 targets operation next financial year, with later modules built only if specific partner requirements materialize.
- What to watch next quarter: Whether the inventory build converts into shipments as planned, whether the third CNS molecule starts shipping, and whether receivables smoothing actually begins.
CMS: The Growth Engine and Its Lumpiness
- Top-two molecules drove the quarter: Commercial CMS projects contributed the majority share of revenue, with the top two commercial CMS molecules as the primary growth drivers.
- New block commissioned but not yet shipping: A ₹128 crore block for one molecule was capitalized and validated in Q2; commercial shipments will start only going forward.
- Third molecule (CNS) imminent: A CNS product will start shipping in the next month or two; it is a typical volume product, neither low nor very high volume.
- Pipeline churn is routine: One intermediate was added in Phase-3 for a novel oncology therapy; one old commercial molecule was removed because it has been generic for some time and Neuland will not pursue it further.
- No concrete commercial visibility beyond 12-18 months: Other than the one molecule around the corner, management confirmed no direct confirmed visibility of commercial projects for the next 12-18 months.
- Exclusivity unlikely with large pharma: Larger pharma companies maintain business continuity management practices that make exclusive relationships improbable.
Saharsh Davuluri: "Building exclusive relationships, especially as you start working with larger pharma companies, is not something of a likely scenario because of business continuity management practices."
Working Capital: The Quarter's Real Drag
- Inventory loaded upfront for expected sales: Inventories rose by ~₹155-160 cr from April to September because the company built inventory in anticipation of a step-up in sales; optimization is targeted over the next five months.
- Receivables skewed by production timing: Production completes in the last month of the quarter, creating a natural receivables spike; the company is attempting to even production and selling over three months, but this will take time because the business starts production in month one and completes in month four.
- Pre-cash flow turned negative: ₹141 crores negative due to the working capital build and CAPEX.
- Receivables smoothing targeted by March: Steps have already started, and the company hopes to have evened out receivables by the end of March.
GDS: Prime Products Step Up, Specialty Stays Lumpy
- Ezetimibe moved from specialty to Prime and is thriving: It was a strong specialty contributor in the past and is now a leading top-two contributor to Prime; it will continue to drive Prime's growth.
- Mirtazapine also contributed well: Both Ezetimibe and Mirtazapine delivered good contributions to GDS.
- Specialty segment inherently uneven: The specialty segment handles small-volume products (hundreds of kgs or tens of kgs) which are inherently lumpy; some molecules are only commercial in a few markets and not yet fully commercialized across all markets, leading to quarters or even years where nothing seems to happen.
- Sterile products contributed in a subdued quarter: Paliperidone and aripiprazole contributed within the specialty segment.
- GDS growth optimism is tempered by timeline: Management remains optimistic about GDS business growth, but it will pan out slowly over, if not this financial year, the next financial year.
Development Pipeline and Revenue Dynamics
- Development revenues were low this quarter: Several new projects are in process development or scale-up but have not yet shipped.
- A commercial launch quantity effect has faded: A product that was close to commercialization contributed significantly from launch quantity, and that effect has now gone from development revenues.
- Phase-3 transitions could bring future revenues: As customers move from Phase-2 to Phase-3, certain revenues are anticipated from products going into Phase-3.
- Project pipeline expected to increase: Management expects an increase in the number of projects across tables over the next 12-18 months, describing them as high-quality projects.
- R&D modernization underway: The company is modernizing its R&D setup with parallel synthesizers and other tools to recruit more skilled scientists.
Peptide Facility: A Capacity Option, Not a Commitment
- Four-module facility under construction: Module-1 will be ready and operational by next financial year; another module has civil work ready but is unequipped.
- Modules 3 and 4 are contingent: They will be built later based on how business tracks, and only if partners have extraordinarily large or specific requirements.
- No kg capacity disclosed: Management gave a detailed explanation of capacity determinants but no specific number, stating it depends on the process.
- Facility sized to attract most commercial opportunities: The facility being built is large enough to attract most commercial opportunities as-is.
Margins: The 30% Question
- Gross margin expanded sharply: 60.1% vs 56.3% in Q2FY25, including manufacturing and other direct costs.
- Operating leverage from CMS mix drove EBITDA: Revenue growth led to operating leverage with the business mix tilting toward CMS.
- 30% is representative, not guaranteed: Management said 30% EBITDA margin is representative of the nature of the business; directionally, with better operating leverage and healthy mix evolution, it is reasonable to assume these margins could be visible, but exchange rates, raw material prices, and business mix could be dampeners.
- Not a set number or guidance: Management explicitly stated the 30% figure is not a set number or guidance.
Saharsh Davuluri: "I think this quarter, what we have seen, 30% EBITDA margin, I think is representative of the nature of the business. Whether it is going to be sustainable or not is something that we may not be able to comment directly."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Inventory optimization | Bring inventory to a natural flow from the current ~₹155-160 cr build-up | Next five months |
| Receivables smoothing | Even out receivables through steps already started | By end of March |
| Third molecule (CNS) commercial shipment | Start shipping a CNS product | Next month or two |
| Long-awaited molecule commercialization | Start commercial shipments | Soon this year |
| Peptide Module-1 operational | Module-1 ready and operational | Next financial year |
| Project pipeline increase | Increase in number of projects across tables | Next 12-18 months |
| New business deliveries | New business expected | Next 12-18 months |
| GDS growth | Optimistic about growth, but will pan out slowly | If not this FY, next FY |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Total income | ₹516 crores, +63.7% YoY vs ₹315 crores in Q2 FY25 |
| EBITDA | ₹156.9 crores, margin of 30.4% |
| Gross margin | 60.1%, vs 56.3% in Q2 FY25 |
| Profit after tax | ₹96.5 crores, vs ₹32 crores in Q2 FY25 |
| EPS | ₹75.18 per share |
| Working capital | 155 days of sales |
| Free cash flow | negative ₹141 crores for the quarter |
| Net debt | negative ₹6.6 crores |
| CAPEX | ₹91 crores for the quarter, ₹170.7 crores for H1 |
| R&D scientist headcount | 385, up from 360 |
| CMS pipeline: new commercialization expected | 1 molecule, shipments expected to start in the next month or two, a CNS product |
| CMS pipeline: commercial visibility next 12-18 months | No concrete visibility beyond the one molecule nearing commercialization |
| Peptide facility investment (Module-1 plus civil for Module-2) | ₹250-280 crores ballpark |
| Inventory increase (April to September) | ₹155-160 crores rise |